Pimecrolimus is safe and effective in treating atopic dermatitis

Journal of Pediatrics

Volumn 167, Issue 5, 2015, Pages 1169-1172

  Eichenfield, Dawn Z ^a   Eichenfield, Lawrence F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PIMECROLIMUS; DERMATOLOGICAL AGENT; TACROLIMUS;

ATOPIC DERMATITIS; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFANT; LONG TERM CARE; MULTICENTER STUDY (TOPIC); NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; DERMATITIS, ATOPIC;

DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; TACROLIMUS;

EID: 84945243691     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2015.08.060     Document Type: Article

References (3)

1. D.J. Margolis, K. Abuabara, O.J. Hoffstad, J. Wan, D. Raimondo, and W.B. Bilker Association Between Malignancy and Topical Use of Pimecrolimus JAMA Dermatol 151 2015 594 599
2. L. Legendre, T. Barnetche, J. Mazereeuw-Hautier, N. Meyer, D. Murrell, and C. Paul Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis J Am Acad Dermatol 72 2015 992 1002
3. L.F. Eichenfield, W.L. Tom, T.G. Berger, A. Krol, A.S. Paller, K. Schwarzenberger, and et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies J Am Acad Dermatol 71 2014 116 132